Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.

OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.

Jiangsu Jiande Biopharmaceutical Co., Ltd., established on 2011-07-22, The scope of business includes the research and development of biopharmaceuticals,consult,transfer(Excluding production and sales).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. Its products include fluorescent label protein, immune-checkpoint protein, and cytokine. The company was founded on July 22, 2010 and is headquartered in Beijing, China.

Jiangsu Simcere Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Simcere Medical Diagnostics Co., Ltd., is a Chinese company located in Nanjing. The firm manufactures and sells pharmaceutical products. It was founded in 1995.

Jiangsu Xiansheng Pharmaceutical Research Co., Ltd., established on 2004-02-10, Business scope includes licensed business items:No general operating items:medical products,Research on medical diagnostic reagents,Technology transfer and related technical consulting services.Self-operated and agent import and export business of various commodities and technologies.*

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Shandong Nomaibo Biomedical Technology Co., Ltd., established on 2014-05-15, Business scope includes biological products and pharmaceuticals,Biochemical reagents,Clinical Diagnostic Reagents,R&D and technical consultation of medical devices,technology transfer,Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Jiangsu Nomaibo Biomedical Technology Co., Ltd., established on 2014-07-02, Business scope includes biological products,medicine,Technology research and development of medical devices,technical consulting,technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shanghai Junshi Biosciences Co., Ltd. engages in the discovery, development, clinical research, and commercialization of biopharmaceutical drugs. Its products include toripalimab injection, UBP1211, JS002, and UBP1213. The company was founded by Zhuo Bing Zhang and Ji Kuan Shan on December 27, 2012 and is headquartered in Shanghai, China.

GlaxoSmithKline Intellectual Property Ltd., a subsidiary of GSK Plc, is a company headquartered in Brentford, UK, that provides business support services.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies and carrying out research and development activities.

Chengdu Weikang Biotechnology Co., Ltd., established on 2017-04-07, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Class II Medical Device Leasing;Class I Medical Device Leasing;Import and export;Technology Import and Export;Specialty Chemicals Sales(Free of Hazardous Chemicals);Instrument sales;Experimental analysis instrument sales;Drug testing equipment sales;Glassware Sales;Optical Instrument Sales;Wholesale of computer software, hardware and auxiliary equipment;software sales;Internet equipment sales;Domestic trade agent;Health Consulting Services(Does not include medical services);Medical Research and Experimental Development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Class III Medical Device Leasing;pharmaceutical production;Drug Wholesale;Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

GlaxoSmithKline Intellectual Property Management Ltd., part of GSK Plc, is a British company located in Brentford. The firm provides business support services.\nThe company says this about itself: The company is a member of the GlaxoSmithKline Group (the \"Group\"). The company's principal activities are the development, enhancement, maintenance. protection and exploitation of intellectual property assets owned by the company which may include but is not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Part of AstraZeneca PLC, Cambridge Antibody Technology Group Ltd. is a British company located in Cambridge that functions as an holding company whose subsidiaries researches, develops and exploits molecular engineering products. It was founded in 1996.